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• HSCT is a curative option for many patients 
(pts) with hematological malignancies.  
• Significant advances in supportive care and 
conditioning regimens over the past decade 
have allowed the extension of this therapy to 
older individuals.  
• Information regarding the outcomes of this older 
subset of pts undergoing HSCT is limited, 
especially those undergoing haploidentical (HI) 
HSCT.  
• Factors associated with decreased overall 
survival in patients above the age of 60 
undergoing HSCT using the 2 step approach 
included older age (>66) and lower KPS 
(70/80%) in a multivariate analysis. 
• Factors associated with higher non-relapse 
mortality were older age (>66), lower KPS 
(70/80%), use of myeloablative conditioning, 
male gender and a lower CD34 dose. 
• Haploidentical or matched related HSCT 
utilizing the 2 step approach are associated 
with acceptable outcomes in older pts.  
• Age and lack of a MR donor should not be 
barriers to HSCT if patients are fit.  
• Patients with lymphoma and controlled 
myeloid malignancies fared better in this 
older population. 
Introduction
Methods
Results
Conclusions
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Patient Characteristics: 
Number 28 34 
Median Recipient Age 
(range) 63 (60-68) 68 (60-78) 
Median Donor age 
(range) 36 (19-70) 44 (24-68) 
Age>65 (%) 8 (28) 26 (77) 
Sex (M/F) 19/9 21/13 
Median CD34 cells  
(x 106/kg) 4.41 (2.1-10) 4.44 (1.4-10.6) 
CD 3 cell dose (x 108/kg) 2 2 
Donor Source 
Haploidentical (%) 23 (82) 33 (97) 
Matched Related (%) 5 (18) 1 (3) 
Disease 
AML/MDS 23 (82) 20 (59) 
ALL 1 (4) 1 (3) 
NHL 4 (14) 11 (32) 
Other 0 2 (6) 
Active disease at time of 
HSCT (%) 19 (68) 25 (74) 
AML/MDS 15 (54) 14 (41) 
NHL 4 (14) 9 (26) 
Others 0 2 (6) 
KPS 
60 % 1(4) 0 
70-80% 5 (18) 12 (35) 
90-100% 22 (79) 22 (65) 
HCT-CI 
0 3 (11) 6 (18) 
1-2 10 (36) 8 (24) 
3 15 (54) 19 (56) 
• Multivariate statistics using cox regression 
analysis identified the following factors 
affecting: 
I. Overall survival: 
• HCT-CI (0 vs >0) and presence of active 
disease at the time of transplant had a strong 
trend with decreased OS on univariate 
statistics (p= 0.07 and p= 0.08 respectively) 
II.  Non-Relapse Mortality: 
• After a median follow-up of 8 months (range 
1-74), 57% of pts were alive.  
• Relapse related mortality was 18% while non-
relapse related mortality was 26%. 
• No rejections or engraftment failures were 
observed.  
• GVHD was controlled in all cases with steroids 
and/or photopheresis. 
Outcomes: 
Median ANC recovery 
(days) 11 11 
Median Platelet recovery 
(days) 16 20 
aGVHD II-IV (%) 9 (32) 12 (35) 
aGVHD III-IV (%) 0 3 (9) 
cGVHD (%) 3 (10) 0 
Cause of Death 
Relapse 4 (14) 7 (21) 
Non-Relapse Mortality 
(%) 7 (25) 9 (27) 
Infection 2 (7) 3 (9) 
Toxicity 4 (14) 4 (12) 
GVHD 1 (4) 2 (6) 
The 2 Step Approach
Conditioning* Lymphocytes  2 Days Rest  CY x 2   Stem Cells 
(2x108 CD3+/kg) 
	 	 
Donor Donor CD 34  
(60 mg/kg/day)  
Tacrolimus + MMF 
* Myeloablative (MA) = 12 Gy TBI over 4 days 
* Reduced Intensity (RIC) = 4 days  of Fludarabine 30mg/m2 + Cytarabine 2gm/m2 or Thiotepa 5mg/kg  
Results
Objectives
• To describe the outcomes of patients 60 years 
of age or older undergoing haploidentical and 
matched related (MR) HSCT using the 2-step 
approach. 
• We did a retrospective chart review of 
outcomes in pts 60 years of age or older 
enrolled on our 2 step haploidentical1,2,3 or 
matched related HSCT trials.  
• Details of the 2-step approach are shown in 
figure 1. 
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Variable Hazard  Ratio 
  95% CI p-
Value  Lower Upper 
KPS 60-80 vs 90/100 6.2 2.74 14.02 <0.001 
Age 60 – 78 years 1.12 1.01 1.23 0.033 
Variable Hazard Ratio 
  95% CI p-
Value Lower Upper 
KPS 60-80 Vs 90/100 7.37 2.48 21.94 <0.001 
Age 60 – 78 years 1.37 1.11 1.68 0.003 
Conditioning MA vs RIC 6.6 1.15 37.87 0.034 
CD34 Dose 
(x 108/kg) 1.4 – 10.6   0.67 0.46 0.96 0.029 
Recipient 
gender M vs F 4.82 1.3 17.87 0.019 
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Survival in Months 
Each of the 
following risk 
factors receive 1 
point: 
•Age > 66 yo 
•KPS < 90 
•HCT-CI >0 
P < 0.004 
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AML/MDS Patients NOT in CR at HSCT 
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